FDA Expands Use of Approved Breast Cancer Drug : RushPRNews - Newswire & Global Press Release Distribution

 
Bookmark and Share

FDA Expands Use of Approved Breast Cancer Drug

February 1, 2010

Washington D.C. (RPRN) 02/01/10 — Provides oral regime for hormone positive and HER2-positive advanced breast cancer

The U.S. Food and Drug Administration today approved Tykerb (lapatinib) in combination with Femara (letrozole) to treat hormone positive and HER2-positive advanced breast cancer in postmenopausal women for whom hormonal therapy is indicated.

HER2 is a protein involved in normal cell growth. It is found on some types of cancer cells, including breast cancer cells. In hormone positive breast cancer, the presence of certain hormones contributes to breast cancer growth. In HER2-positive breast cancer, stimulation of the HER2 receptor contributes to cancer cell growth. Breast cancer is the second leading cause of death among women. More than 192,000 women will be diagnosed with breast cancer this year.

“This drug combination of Tykerb plus Femara provides women being treated for advanced breast cancer with an important treatment option. This entirely oral treatment regimen works by targeting both HER2 and the hormone receptors, thereby slowing the cancer cells’ ability to grow or spread,” said Richard Pazdur, M.D., director of the Office of Oncology Drug Products, in the FDA’s Center for Drug Evaluation and Research.

Women with HER2-positive disease receiving the Tykerb plus Femara combination more than doubled the time they lived without the cancer progressing compared with those receiving Femara alone (35 weeks vs. 13 weeks). Women in the company sponsored study were randomized to receive Tykerb plus Femara or Femara alone. It is too early to determine whether an improvement in overall survival will be observed in the clinical trial.

Tykerb works by depriving tumor cells of signals needed to grow. Tykerb enters the cell and blocks the function of the HER2 protein.

Tykerb was initially approved in combination with a chemotherapy drug, Xeloda (capecitabine) in 2007. This combination was used to treat women with advanced breast cancer tumors with the HER2 protein who had received prior treatment with chemotherapy drugs, including an anthracycline and a taxane, and Herceptin (trastuzumab), an anti-cancer antibody used to treat HER2-positive advanced breast cancer.

Safety information from this study was consistent with previous Tykerb clinical studies in advanced breast cancer. The most commonly reported side effects of the combination were diarrhea, rash, nausea and fatigue. Treatment with Tykerb also has been associated with decreases in heart function, liver damage, and lung tissue inflammation. Fetal harm may occur if used to treat advanced breast cancer in pregnant women. Patients should talk to their health care provider about the potential side effects, drug interactions, and other medical conditions.

 

Tykerb is marketed by Collegeville, Pa.-based GlaxoSmithKline.
Femara is marketed by Lebanon, Pa.-based Novartis AG.

 

For more information:

 

FDA Office of Oncology Drug Products
http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm091745.htm

 

National Cancer Institute – Breast Cancer
http://www.cancer.gov/cancertopics/types/breast

 

RSS Feed for FDA News Releases [what is RSS?]

About the author:

FDA is an agency within the Department of Health and Human Services and consists of seven centers and offices

Click here to see all news from this author/company

Filed Under: FDA- Pharmaceutical news, Health and Fitness, Food-Nutrition, Lifestyle, PRESS RELEASE

RUSH PR NEWS newswire and press release services at rushprnews.com / Anne Howard annehowardpublicist.com

Content- Legal Responsibility - All material is copyrighted - You may repost but you MUST link back to the original post on your page and acknowledge Rush PR News as the news source. Rush PR News is not legally and/or morally responsible for content of press releases, opinions expressed or fact-checking.

Rush PR News cannot be held legally responsible for material published and distributed through its newswire service or published in its press-room and therefore cannot be sued for published material. Third-party must be contacted directly to dispute content.

Rush PR News is not the contact for material published.

RSSFeed PRESS & SOCIAL MEDIA RELEASES

Coalition Joins National Coalition for Infant Health

Washington, D.C. 06/25/15 · Newborn Foundation News: Newborn Health leaders convene in DC...

RushPRnews now offers digital news sites +Targeted News outlet Broadcast

SAN FRANCISCO/MONTREAL 06/22/15 · Your press release to be featured on at...

Save our Skies Santa Cruz Launches Petition Urging FAA to Stop the Jet Noise

Santa Cruz, California 06/21/15 · Outraged Citizens fight FAA's NextGenprogram to reclaim quality...

Ultraseal International makes casting impregnation even easier with fully automated two-stage process

Dusseldorf, Germany 06/17/15 · Ultraseal International is living up to its global...

Army Officials and Ameresco Join to Commemorate Completion of Energy Efficiency and Solar Project

FRAMINGHAM, Mass. & ADELPHI, Md. 06/16/15 · Army Officials and Ameresco Join to Commemorate Completion...

Ultraseal International celebrates second exporting award this year

Birmingham, West Midlands, UK 06/16/15 · Ultraseal International is celebrating a double success after...

The American radio host, Ed Tyll issues death threat, alleges a French-Canadian publisher

Montreal, Quebec, Canada 06/15/15 · On June 5, the controversial radio host, Edward...

Planwise: Best Mortgage Calculator Since 1993

San Francisco, CA 06/09/15 · Planwise Launches Pinterest Style Mortgage Calculator  Planwise launches PlanwiseConnect,...

Israel’s Start Tel Aviv offers global opportunity for Canadian tech startups

Ottawa,Canada 06/09/15 · Israel’s Start Tel Aviv offers global opportunity for...

Demand for Independence of Punjab Echoes in San Francisco

San Francisco 06/08/15 ·  Thousands of North American Sikhs converged in downtown...

World Renowned Casting Director Appointed to Eagle Arts Academy Board of Directors

Los Angeles, CA 06/06/15 · Eagle Arts Academy is pleased to announce that...

MultiClonal Therapeutics Researchers Report Today Breakthrough in Cloning Human “Ground State” Stem Cells

Farmington,CT 06/05/15 · An international consortium including investigators at MultiClonal Therapeutics,...

Time to increase your public relations impact

SAN FRANCISCO 06/04/15 ·                 Your « SPRING2015-2 » Coupon is here! And with it...

Financial Fraud Lengthy Prison Term for Advance Fee Fraudster

Washington, DC 06/02/15 · Like many successful con men, William C. Lange...